You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
Ms drug trials. The remaining 34 clinical trials are included in the Table.
- Ms drug trials. Find clinical trials and other clinical studies conducted at Johns Hopkins. ’s Medicines and Healthcare products Regulatory Agency (MHRA) has cleared Pheno Therapeutics to initiate a first-in-human Phase 1 clinical trial to test its oral candidate PTD802 in Sep 23, 2024 · The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to MS progression. gov had more than 2,000 clinical trials related to multiple sclerosis (MS). Dec 16, 2024 · Medically Reviewed This Drug Is Attempting to Rebuild Myelin in MS Scientists hope that a new multiple sclerosis med called PIPE-307 that’s now in clinical trials could help repair nerve damage. Figure. Clinical trials are research studies, involving human participants, that are designed to test the safety and efficacy of new or existing interventions (i. Addressing disease progression as a treatment goal in MS is challenging due to several factors. Apr 26, 2025 · A UCSF neurologist who has spent 40 years studying multiple sclerosis helped develop a game-changing drug that may help most people with MS live full lives. -- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced new results from the Phase 3 DAYBREAK open-label extension trial, demonstrating the long-term efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (MS). Scientists are finding new and innovative ways to stop the immune system attacking myelin. These trials aim to understand therapy effectiveness in managing MS. Despite the success of disease-modifying treatments in relapsing multiple sclerosis, for many individuals living with multiple sclerosis, progressive disability continues to accrue. Since 2014, several immunomodulatory approaches that have modest but clinically meaningful Aug 8, 2024 · Treatment with PIPE-307, currently in Phase 2 testing for RRMS, was shown to promote remyelination in a mouse model of multiple sclerosis. The company is in the Feb 22, 2024 · The first US trials of engineered cells to treat multiple sclerosis have started recruiting volunteers, raising hopes for a new therapeutic option for this devastating neurodegenerative disease Ocrelizumab was developed for primary progressive and relapsing MS. You can register your interest in taking Aug 29, 2018 · We enrolled patients with primary or secondary progressive multiple sclerosis in a phase 2 randomized trial of oral ibudilast (≤100 mg daily) or placebo for 96 weeks. Mar 26, 2025 · Tiziana Life Sciences has begun dosing subjects in a Phase II trial of foralumab for non-active secondary progressive multiple sclerosis. But tolebrutinib did Sep 27, 2024 · This edition of “What’s New in MS Research” reflects the extent and breadth of efforts to better treat multiple sclerosis and to enhance the overall health of people living with the condition. If you have MS, your participation in clinical trials can influence advancements in MS research. May 26, 2025 · Therefore, additional studies are needed before human clinical trials can commence. Over 20 FDA-approved disease-modifying therapies May 29, 2025 · Explore the latest advancements in remyelination research for multiple sclerosis, from stem cells to small molecules, and discover what’s on the horizon for therapeutic development. Immune cell numbers and locations depend on disease stage. Jan 19, 2017 · In this phase 3 trial, we randomly assigned 732 patients with primary progressive multiple sclerosis in a 2:1 ratio to receive intravenous ocrelizumab (600 mg) or placebo every 24 weeks for at Multiple sclerosis (MS) is an immune-driven disease that affects the central nervous system and is characterized by acute-on-chronic demyelination attacks. Oct 28, 2025 · In this edition of Trials to Watch, Clinical Trials Arena looks into the potential of three drugs in Phase III development for the autoimmune neurological condition, multiple sclerosis (MS). May 31, 2023 · The French drugmaker presented phase 2 data that suggest its second-generation drug candidate may be safe and effective in multiple sclerosis. Studies enrolling diverse populations are monitored to ensure that the rights and safety of all participants are protected. The way it is designed means several drugs Mar 25, 2025 · The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients. Mar 24, 2025 · A new nasal spray treatment called foralumab may offer hope for those living with multiple sclerosis (MS). Oct 24, 2025 · Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. This clinical trial is focused on studying the effects of a new treatment for people with multiple sclerosis (MS) who experience chronic neuropathic pain. Mar 14, 2025 · MS is a chronic, immune-mediated disease affecting the central nervous system, with no known cure and varying levels of impact on individuals. Delivery methods that are used to modulate effective and long-lasting immune Jan 19, 2017 · In this phase 3 trial, we randomly assigned 732 patients with primary progressive multiple sclerosis in a 2:1 ratio to receive intravenous ocrelizumab (600 mg) or placebo every 24 weeks for at Sep 2, 2024 · By Ludwig Burger (Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive Multiple sclerosis (MS) is an immune-driven disease that affects the central nervous system and is characterized by acute-on-chronic demyelination attacks. Aug 9, 2024 · Scientists have developed a new treatment that may help regenerate myelin around nerve cells, and potentially reverse the damage caused by multiple sclerosis (MS). And they're also developing drugs that could reverse damage and protect nerves. Feb 9, 2024 · Search for Clinical Trials - scientific studies that test the safety and effectiveness of new treatments for MS and other diseases. e. K. In two Phase 3 studies of people with relapsing forms of MS, the drug tolebrutinib wasn’t better than another Sanofi medicine, Aubagio, at reducing the rate of disease flare-ups. Learn more and discover opportunities to participate near you. Feb 15, 2024 · A team of experts published a review of recent clinical trials for progressive MS, discussing recent progress and remaining issues. Nov 1, 2024 · Drug companies are exploring many different medications to treat—and potentially even cure—multiple sclerosis, including these seven medications. It is a major cause of global neurological disability, and its prevalence has increased in Oct 2, 2024 · Researchers have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. Clinical trials for new treatments of multiple sclerosis (MS) have led to the approval of more than twenty medicines for the treatment of MS. The purpose of this study is to better understand multiple sclerosis (MS) in children and adolescents, to learn if it differs from adult MS and to investigate if genes or environmental exposures or a combination of both put children and adolescents at risk for getting MS. Are you a healthcare provider looking for information on multiple sclerosis (MS) clinical trials? Read more here. Sep 2, 2024 · Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a study Mar 6, 2024 · Convelo Therapeutics is developing two experimental oral treatments to promote myelin repair in multiple sclerosis (MS) and both have shown promise in preclinical models. The remaining 34 clinical trials are included in the Table. May 1, 2025 · Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis. The researchers and clinicians who gathered in late February in West Palm Beach, Florida, for the 2025 ACTRIMS Forum shared data The goal of clinical trials is to determine the benefits and risks of the new treatment compared to the placebo or active comparator in a specific group of people. Oct 15, 2025 · Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters CSF markers of chronic inflammation. 2 days ago · Biogen's efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China's InnoCare last year for $125 Tolebrutinib is a new drug being investigated for the treatment of relapsing, secondary and primary progressive MS. Mass General Brigham researchers recently completed a phase 1 clinical trial of foralumab, which shows promise in reducing MS symptoms and improving the quality of life for those affected by this condition. Jan 28, 2025 · The clinical trials and other analyses to follow examine topics ranging from the impact of discontinuing or switching disease-modifying therapies (DMTs), to associations between MS and weight gain and COVID-19 infection. How to interrupt the complex pathological processes underlying progression remains a daunting and ongoing challenge. In a study of 129 patients with relapsing disease, the drug, called frexalimab, significantly reduced the number of Dragonfly Research, our research arm, is currently conducting clinical trials for relapsing and progressive forms of multiple sclerosis (MS). It is a major cause of global neurological disability, and its prevalence has increased in Key Clinical Trial Findings for BTK Inhibitors: Evobrutinib and Tolebrutinib The first results for BTKi in relapsing MS came out in December 2023, and showed that the drug Evobrutinib was no better than Teriflunomide (Aubagio) in reducing the annualized relapse rate or disease progression in relapsing MS. Jun 24, 2025 · Multiple Sclerosis Market Dynamics The multiple sclerosis market is shaped by a complex interplay of scientific innovation, unmet medical needs, competitive drug development, and evolving Sep 3, 2024 · Dive Brief: An experimental Sanofi medicine failed two studies in multiple sclerosis but met its main objective in a third trial in a less common form of the disease, the company said Monday. UCSF offers trials testing Clemastine Fumarate's role in repairing nerve coverings and studying Ocrelizumab's impact on immune cells. Decades of neuroimmunologic research substantiate the role of innate and adaptive immunity in the pathophysiology of relapsing and progressive courses of multiple sclerosis (MS). Jan 5, 2024 · The FDA has cleared a Phase 2 clinical trial to test Kyverna's cell-based therapy KYV-101 for treatment-resistant forms of progressive MS. Octopus: Optimal Clinical Trials Platform for Multiple Sclerosis This is a revolutionary trial that will transform the way we test treatments for Progressive Multiple Sclerosis (MS). May 22, 2025 · This edition of “What’s New in MS Research” includes a representative sampling of those presentations – a dozen items that cover everything from promising potential treatments and biomarkers that can help predict disease course, to insights into the unmet needs of people with MS and the factors that shape their decisions about disease-modifying therapies. Find out about multiple sclerosis (MS) clinical trials that are available to take part in and where they are. Sep 20, 2024 · For the first time, a phase 3 trial has shown a drug can slow down disability progression in people with secondary progressive MS who don’t have relapses. Mar 11, 2025 · Clinical trials in multiple sclerosis treatment at UNM Health mean our patients, our doctors, and our trainees are at the leading edge of groundbreaking advances. The target action date for the FDA decision is September 28, 2025. Jun 6, 2025 · A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over 2 years of follow-up with few adverse events. Although several drugs are approved for MS, their efficacy in progressive disease is modest. Apr 4, 2023 · Ailsa, now 47, is taking part in a groundbreaking new trial, which is looking into whether existing drugs can be repurposed to help slow MS progression. We're really close to finding new MS treatments. Apr 4, 2023 · Existing trial patients who prove to be on ineffective drugs can swap to a new arm, and are allowed to continue any other MS disease-modifying drugs they may already be taking. To learn more about this medication, the manufacturer plans to conduct a phase 3 Mar 10, 2025 · Today, we take a closer look at the most recent research and interventional clinical trials targeting multiple sclerosis. But tolebrutinib did Aug 5, 2020 · A newly completed phase 3, multicenter clinical trial has found that an immune-modulating drug can silence inflammatory disease activity in a large majority of patients with relapsing multiple sclerosis (RMS) – the most common form of the illness, in which symptoms wax and wane. Aug 5, 2024 · A new drug, PIPE-307, shows promise in reversing multiple sclerosis (MS) damage by promoting myelin regeneration around nerve cells, potentially restoring movement and function. Another phase 3 trial for people with primary progressive MS is ongoing. The treatment being tested is an oral solution called Satalliv, which contains two active substances: Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). To select the most promising trials with reasonable probability for an innovative MS drug to be approved by the Food and Drug Administration (FDA), only currently active (recruiting or not recruiting) or recently completed (within the last 3 . In two other phase 3 trials, tolebrutinib also slowed progression in relapsing MS. Jul 25, 2025 · There are hopes a clinical trial in Torbay could be a game-changer for patients with advanced MS. Help advance science by participating in clinical research. Octopus is a revolutionary trial that will transform the way we test treatments for progressive MS. Aug 5, 2020 · A newly completed phase 3, multicenter clinical trial has found that an immune-modulating drug can silence inflammatory disease activity in a large majority of patients with relapsing multiple sclerosis (RMS) – the most common form of the illness, in which symptoms wax and wane. Octopus is open to recruitment! Platypus, the Australian extension of the trial will be Mar 25, 2006 · The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients. Designing immunotherapeutics, drugs, and anti-inflammatory reagents has been at the forefront of autoimmune research, in particular, multiple sclerosis, for over 20 years. ’s Medicines and Healthcare products Regulatory Agency (MHRA) has cleared Pheno Therapeutics to initiate a first-in-human Phase 1 clinical trial to test its oral candidate PTD802 in May 23, 2025 · How MS drugs are developed and tested in clinical trials to be sure they are safe and effective. Apr 8, 2025 · In a phase 3, double-blind, placebo-controlled, event-driven trial, we randomly assigned participants with nonrelapsing secondary progressive multiple sclerosis, in a 2:1 ratio, to receive Oct 15, 2025 · The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS). Without the participation of people with MS, it would be impossible to develop new and better solutions. The TREAT-MS Clinical Trial for Multiple Sclerosis (MS) Patients An Exciting Interview from the PCORI Annual Meeting Ellen Mowry, an associate professor of neurology at Johns Hopkins University, is the principal investigator on a PCORI-funded pragmatic clinical study that aims to provide clarity for clinicians on which disease modifying therapy should be prescribed for patients living with Jun 12, 2024 · A generation ago, a diagnosis of multiple sclerosis was a guarantee of a debilitating disease that would leave the patient wheelchair bound, and worse. Positive results from phase 3 trials into relapsing and non-relapsing secondary progressive MS have been announced. The results build on two harmonized Phase I clinical trials, focusing Oct 13, 2025 · Relapsing-remitting multiple sclerosis causes episodes of symptoms followed by recovery periods. 2 days ago · Roche has revealed good results from a phase 2 trial of its oral BTK drug fenebrutinib in relapsing multiple sclerosis as it waits for phase 3 data. The primary efficacy end Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system characterised by inflammation, demyelination and neurodegeneration. Read about how it works and the latest clinical trial results. Sep 20, 2024 · Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate tolebrutinib, linking the BTK inhibitor to a 31% delay in time to onset of May 22, 2024 · The results of a phase 2 clinical trial suggest that the drug ibudilast might help reduce the progression of MS. Feb 29, 2024 · PRINCETON, N. Of the resulting 147 trials active (noncompleted, recruiting or nonrecruiting) and completed trials, those with less than 100 participants and those testing drugs with identical mechanisms of action with already available MS drugs (eg, target S1P receptors or CD20+ cells) were excluded. Sep 27, 2024 · This edition of “What’s New in MS Research” reflects the extent and breadth of efforts to better treat multiple sclerosis and to enhance the overall health of people living with the condition. A biology teacher and mother-of-two has become the first UK patient to receive a "gamechanger" therapy to treat multiple sclerosis (MS). J. A smarter way of testing potential treatments, it could deliver life-changing new treatments up to three times faster. May 19, 2025 · Medically Reviewed A New Drug Shows Promise in Treating Secondary Progressive MS The medication may be the first to help delay progression in more advanced forms of multiple sclerosis. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 93 clinical-stage projects*, 36 of which are in phase 3 or have been submitted to regulatory authorities for approval Aug 8, 2024 · Treatment with PIPE-307, currently in Phase 2 testing for RRMS, was shown to promote remyelination in a mouse model of multiple sclerosis. These data (Poster #P090) and nine additional abstracts will be presented at the 9 th annual Americas Sep 2, 2005 · Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis In the HERCULES study, tolebrutinib met the primary endpoint in delaying time to onset of confirmed disability progression in people with nrSPMS, a population for which there are currently no approved therapies May 31, 2023 · Sanofi on Wednesday said an experimental multiple sclerosis drug succeeded in a mid-stage trial, giving the company the confidence to bring the medicine into pivotal testing next year. In December 2019, the US Library of Medicine database ClinicalTrials. Jan 21, 2025 · The U. Clinical trials help to determine if treatments and other interventions are safe and effective. Follow UCSF’s role in what some call the golden age of MS research and care. Frexalimab in Relapsing Multiple Sclerosis and Non-Relapsing Secondary Progressive Multiple Sclerosis: Design of Phase 3 FREXALT and FREVIVA Trials Apr 10, 2025 · This Experimental Clinical Trial Helped Those With Advanced MS A new experimental drug is giving hope for people living with advanced multiple sclerosis (MS), particularly those with non-relapsing secondary progressive MS (SPMS), a harsh form of the disease marked by worsening neurological function and increasing disability over time. , drug, exercise, diet, diagnostic technique, surgical procedure) in improving a certain disease condition, such as multiple sclerosis (MS). May 23, 2025 · How MS drugs are developed and tested in clinical trials to be sure they are safe and effective. See details from this review. Aug 5, 2020 · In two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relapsing multiple sclerosis to receive subcutaneous ofatumumab (20 mg every 4 weeks after 20-mg loading doses Mar 27, 2025 · The annual meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) is one of the premier occasions for the release of new studies on the nature and treatment of MS, and this year’s session continued that trailblazing tradition. How can I take part? Octopus is recruiting people with primary or secondary progressive MS who are aged between 25 and 70 years old. Combining Remyelination Drugs with Immunotherapies The future of MS treatment likely lies in combination approaches that simultaneously target different aspects of the disease. qdnnj e4jb wk5kuk kygcz 3n zibwj 6agw i2 5eto5jt 6w78sj